A Databank Study of Molecular Circulatory Biomarkers in Non-localized Renal and Testicular Cancer Patients


About this study

The purpose of this study is to collect blood and urine specimens from cancer patients with non-localized kidney cancer receiving therapeutic interventions and patients with a diagnosis of testicular cancer. To clinically annotate a registry in the patients enrolled for the purpose of developing new cancer related molecular biomarkers for prognosis and prediction of clinical outcomes. This will include proteomic, genomic and metabolomic based molecular profiling in blood and urine specimens collected from cancer patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:    

  1. Subjects with a histological confirmed diagnosis of testicular cancer who are destined to initiate standard of care therapeutic interventions. This includes testicular cancer subjects with evidence of clinically or biochemically progressive disease post surgical or radiation treatments for localized stage disease as deemed by the treating physician. Biochemical evidence of progressive disease is defined as a serially rising serum tumor marker (AFP-Alpha Feto-Protein; B-HCG-beta human chorionic gonadotropin or LDH). 
  2. Subjects with non-localized kidney cancer being followed or treated at Mayo Clinic as part of standard clinical care.
  3. Age: 18 to 100 years
  4. Subject must be able to sign an informed consent. Informed consent must be signed at the time of enrollment and/or collection of any specimen and/or clinical data (other than PHI needed to screen and identify patients, which will be promptly discarded in a secure fashion if patient is not enrolled on study).

Exclusion Criteria:   

  1. Subjects either incarcerated or with limited decision making capacity.
  2. Subjects clinically judged to be at increased risk of bleeding from phlebotomy.
  3. Subjects with hemoglobin
  4. Subjects with a previous history of known second non-GU malignancy in the past five years.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Brian Costello, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Winston Tan, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions